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ABSTRACT 
In any healthcare sector, the medical device industry plays an important role in reducing 
overall healthcare costs and ensuring effective access to healthcare. However, in developing 
countries such as India compared to the success of the pharmaceutical and biotechnology 
industry, the medical device industry has not witnessed similar growth. In this context this 
paper studies factors and issues that hampered development of the medical device industry in 
India. Specifically it explores the link between regulatory policies and their impact on 
innovation and technology capability development in the Indian medical device industry. 
Further it examines the complex relationship between healthcare regulation, innovation, and 
sustainable development within the context of an increasingly globalising economy. It shows 
crucial role of smart and appropriate regulation in creation of the basic technological 
capabilities, incentivising inclusive innovation and affordable healthcare. 
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1. INTRODUCTION 
In the developing country context science and technology policies plays an important role in facilitating 
or inhibiting growth of a particular sector, industry or market. In healthcare sectors role of these 
policies acquired even more dominant role due to strong linkages between science and technology 
policies in creating human and infrastructural resources for the healthcare industries. In case of 
healthcare industries significant part of technology policies is concerned with devising regulatory 
policies that can ensure development of safe and effective products, therapies and services for all the 
populations. Indeed, as a result of the transformation and intensification of risks, to individuals and 
societies, that are widely associated with the bioeconomy, the regulation of healthcare sectors has 
become extremely important.  
Given importance of healthcare costs and its role in ensuring affordable healthcare for all, it is 
almost impossible to overstate the importance of, or the importance being attached to, the healthcare 
sectors in the modern era. Unsurprisingly, the form, scope, and stringency of regulation have been, 
and continue to be, much discussed, with governments frequently oscillating between tight regulation 
and deregulation. The risk-driven inclination in the healthcare sector has been to regulate, and to 
regulate heavily.   
  A common response to control and direct innovative activities and products in the healthcare 
sectors is to draft statutory instruments, guidelines or codes. These regulatory efforts have tended to 
fragment and complicate innovation systems and product pathways, for which they have been loudly 
criticised. Ultimately, the dominant view that has emerged is that regulation hampers innovation and 
the development of strong and competitive industries or sectors. The studies of regulation in 
healthcare industries clearly points out its impact on shaping innovation, influencing industry structure 
and determining firm level technology strategies. While this can certainly be the case, this paper argue 
that an absence of regulation can be just as damaging to innovation within, or indeed the survival of, a 
field of inquiry or production.  Based on the study of the Indian medical devices sector, this paper 
argue that regulation can have many salutary effects, some of them surprising, so neglecting to 
regulate, or deregulating where frameworks already exist, is not necessarily the way forward. This fact 
may not always be appreciated in jurisdictions with sophisticated legislative and regulatory 
infrastructures containing strong participative mechanisms.  
Over the last decade the Indian pharmaceutical and biotechnology industries has emerged as 
a leading supplier of generic drugs and vaccines to both developing and developed countries, while 
India still imports more than 75% medical devices from advanced countries.  The Indian pharma and 
biotech sectors are categorised as pioneers for developing inclusive innovations that ensured 
accessibility of affordable drugs and vaccines to majority of populations in the developing countries. In 
medical device industries some India firms are involved in developing inclusive innovations but 
struggling to receive market acceptability due to ambiguous regulatory policies. In this context this 
paper studies relationship between regulatory policies and their impact on innovation and technology 
capability development by exploring what role absence of regulation played in hampering or facilitating 
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development of inclusive innovations in the Indian medical device industry. In developing study 
literature development of technological capabilities in high-tech industry such as medical devices has 
remain a neglected area of research. This research aims to fill that gap.  
  Similar to pharmaceuticals and vaccines, medical devices are essential for patient care in 
operating theatres, at the bedside, and even before a patient is admitted into hospital, or after being 
discharged. The regulation of medical technologies is one of the most neglected areas in the health 
policy research. According to the World Health Organization “medical devices” includes everything 
from highly sophisticated computerized medical equipment down to simple wooden tongue 
depressors. In many countries medical devices regulation is still evolving phenomenon as product 
development is associated technological complexities and uncertainties in use.  
 This paper addresses the issue of regulatory vacuums and their impact on capability 
development, highlighting some of the difficulties caused by them. Section two discusses the 
relationship between regulation and innovation and impact of regulation on direction of innovation and 
evolution of a sector. Section 3 presents background of the medical device industry while section 4 
provides details of research methodology used in this research. Section five elaborates on the case 
studies of three Indian medical device firms and discusses key features of inclusive innovations 
developed by these firms. Section six presents the evidence generated by problems associated with 
the regulatory situation in India as it relates to medical device development. This paper conclude that, 
rather than lamenting the existence of regulation policy makers should strive to create ‘smart and 
appropriate regulation’ which optimises opportunities to innovate and thereby benefit from scientific 
pursuits, new technologies and inclusive development.  In short, innovation needs to be in our 
approach towards regulation. 
 
2. REGULATION AND INNOVATION   
Healthcare sectors are perceived as a research focused and supply driven to a much greater 
degree than other manufacturing sectors. However, the extent to which the sector is influenced by 
factors other than science and technology is often underestimated (Chataway et al, 2010). Regulation 
and industrial policy forms an important third pillar to two other strands of (science and technology) of 
healthcare and biotechnological industries. Government aims to stimulate and control innovation 
through variety of routes; some of them are direct such as industrial policy, tax concessions and some 
other are indirect such as infrastructure creations and regulatory policies. For example, the impact of 
government support and regulation can be observed in case of evolution of European and US 
pharmaceutical industry. In 1880 German and Swiss industries were at forefront at development and 
manufacturing of drugs. However with outbreak of World War II US government organised a massive 
research and production effort that focused on the commercial production techniques and chemical 
structure analysis (Henderson et al., 2007). This system significantly improved productivity and led the 
foundations for the industry that helped US industry to leapfrog European pharmaceutical companies.  
In healthcare and biotechnological sector regulation can have similar impact and regulatory policy is 
one of the key instruments of government intervention.  
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2.1 Influences of regulation 
The primary objective for regulation is to ensure safety and efficacy of products for mass 
consumption. Most healthcare and biotechnological products require regulatory approval before 
entering the market. The granting of market approval turns on the provision of data that satisfied the 
regulator that the product is a quality product that is safe and effective, and that there are risk 
management plans in place. This role is paralleled by the European Medicines Agency (EMA), whose 
mission is to foster scientific excellence in the evaluation and supervision of medicines for the benefit 
of public and animal health. Obviously, such regulatory frameworks have significant implications for 
the market-entry of products, including the cost and timing of market entry, all of which affects the 
sustainability of a firm’s market position (Henderson et al., 1998). 
Second key objective of regulation for government is to create a set of incentives and constraints to 
influence behaviour of economic agents with the assumption that these rules will protect public health, 
stimulate development of effective products and ensure quality of those products. Government aims to 
remove information asymmetries and design clear rules for all stakeholders with the use of regulatory 
control (Chitniz, 2002). For example, Cockburn (2004) credits Bayh-Dole Act in 1980 for setting clear 
rules for universities, small business and non-profit organisations to earn on intellectual property rights 
of their inventions. This regulation gave US universities, small businesses and non-profit organisations 
the right to retain intellectual property rights to inventions deriving from federally funded research. It 
allowed individual scientists to launch new biotechnology focused firms, which acted as a “middlemen” 
in the transfer of technology from Universities and established firms. These start-ups developed new 
“architectural competencies that enabled them to act as integrators across research, manufacturing 
and process development and thus played a critical institutional role in emergence of biotechnology 
sector. This regulation allowed emergence of this new institutional innovation that formed foundation 
for rapid emergence of the biotechnology industry in US.  
In some cases regulations has made significant changes to growth of healthcare sectors. For 
example, the ruling in a landmark case of the 1980s, Diamond vs Chakarvarty and Patent and 
Trademark Amendments of 1980s has been credited with the rise of the biotechnology industry. 
Diamond vs Chakarvarty case involved a patent claim on a genetically modified, oil eating bacterium. 
USPTO rejected the claim on the basis subject matter was living organism and ineligible for patent 
protection. In 1981 the US Supreme Court granted extension of patentability to genetically engineered 
bacteria and by that establishing the right for very broad claims (Merges and Nelson, 1994). It created 
tight appropriability regimes and well define rules that led to foundations to emergence of 
biotechnology sector. It is often stressed that the lack of adequate patent protection was a major 
obstacle to the development of the biotechnology industry in Europe. 
  Third important objective of regulation is to create sustainable institutional modes that have 
enough flexibility to accommodate evolution particular set of economic activity For example; in 1990 
the dynamics of the US healthcare market was transformed due to introduction of the Hatch-Waxman 
Act. This act was proposed to incentivise development and production of cheap generic drugs for poor 
populations of the country while ensuring benefits for pharmaceutical firms on their innovative product 
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development. It allowed entry of generics medicines by eliminating the clinical testing aspect. Firms 
could file for generic market entry on the basis of bioequivalence studies and that significantly reduce 
entry barriers for firms operating in generics area. Moreover, the first firm to file an application for 
making a generic equivalent to a branded drug receives a 180-day period of exclusivity, while 
manufacturers of branded drugs are allowed to request a 30-month postponement of the FDA's 
approval of generic drugs that arrive before their patents expire. This regulatory change gave rise to 
affordable generic market, had impact on business models of pharmaceutical firms and opened a new 
market to the leading Indian firms (Kale and Wield, 2008).  In 1980, generics held only 2% of the US 
market (Henderson et al., 1998). 
One example of the way in which policy and regulation have impacted on the evolution of the 
sector in developing countries is provided by rise of Indian pharmaceutical industry as a main source 
of cheap generic medicines all over the world. The Indian government intervened through regulatory 
policies and created an industry with required credentials to better serve the needs of its people (Kale 
and Little, 2007). Shifts in policy and investment encouraged the growth of an industry and generated 
inclusive innovations that helped in satisfying the healthcare needs of poor people with producing 
medicines at an affordable prices being the main concern.   
   
2.2 Perils of regulation:   “Overrgulation” and “overdosed” 
Majority of healthcare and biotechnological products needs regulatory approvals to enter 
markets and that has significant implications on the entry of the product, its cost and on firms’ ability to 
sustain market position once product is approved (Henderson et al.,1998). As a result regulation 
strengthens the government’s authority over all stakeholder and their activities in healthcare and 
biotechnological vale chain. This strong influence of regulation and government control has become a 
contentious area in studies of regulation and innovation. Boundaries of regulation and limits to 
governance have emerged as key areas of focus (Lyal et al.,2009). Regulation is criticised for 
introducing a set of unintended constraints that increases cost and hampers direction of innovation 
(PWC, 2002). Espein (2006) has termed this phenomenon as ‘overdose’ of regulation while Havighurst 
and Richman (2006) calls is ‘overregulation’.  
First key criticism against regulation is that increases cost of innovation. Regulation has a significant 
unintended impact that reaches far beyond simply determining the kinds of products that are 
developed. It creates more unintentional subtle incidental barriers.For example, Cockburn (2004) 
criticises introduction of Bayh-Dole Act of 1980 for rising cost of pharmaceutical R&D. Till introduction 
of this act there was much of movement of ideas, candidate molecules, research materials and 
researchers back and forth across the for profit and non for profit divide. However, introduction of 1980 
Act led to emergence of biotechnology companies, many of which positioned themselves as an 
intermediately sector between academic research institution and Big pharmaceutical firms. Academic 
scientists played a particularly important role in the founding of these intermediately companies. 
Cockburn (2004) argues that some of the increase in R&D spending represents payments for access 
to upstream science of the kind that used to be obtained ‘for free’ by pharmaceutical firms but now 
firms has to pay price in the form of license agreements with biotech firms and universities.  Curtis and 
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Schulman (2006) argues that regulation may profoundly affect cost by stifling innovations in service 
delivery and quality improvements by demanding lot of documentation and paperwork.  
 Second key criticism against innovation is that it stifles creativity by creating barriers to ‘out of 
box’ thinking. Supporting this argument Curtis and Schulman (2006) point out that the presence of 
regulation may effectively prevent disruptive technological improvements from occurring. Based on 
Christensen (2007) theory of disruptive innovation, they suggest that in weakly regulated market, a 
disruptive innovation may emerge because of the low threshold of mandated requirements exist and 
that allows introduction of products with basic features. In highly regulated markets this is not possible 
as products are expected to be of ‘ideal standards’ and these standards exceed the performance 
requirements of the average consumer. In such cases requirements established by regulations might 
be ideal and not optimum and thus exceeds the requirement of basic product application, preventing 
disruptive innovation. For example in weakly regulated Indian automobile sector Tata Motors could 
innovate with material and interiors while designing indigenous car and thus could launch world's 
cheapest car with basic safety features. Tait et al., (2007) provides examples of information 
technology sector. They compare the lightly regulated information and communication technology 
(ICT) sector with the heavily regulated life sciences. In last two decade IT sector has much shown 
greater degree and rapidity of change in products and capabilities arising from technological 
innovation. It is quite evident that these small innovations have basically emerged from small start-up 
companies. In short period of time these small star-ups are able to build up resources and has 
upstaged existing industry players to emerge as a major players on the basis of innovations that 
effectively challenge the status quo. However in a strongly regulated market the performance 
threshold is higher; all products must meet mandated requirements to enter the market. IT sector has 
witness emergence of new dynamic players taking sector forward with their innovations while in 
contrast life sciences sector, has suffered  domination by a relatively small group of multinational 
companies. In healthcare sector regulation now forms an insurmountable barrier to entry for any start-
up company with an innovative idea that might challenge the status quo. Thus under current 
circumstances, regulation prevents development of the radically innovative technologies that could 
provide the opportunities to move the sector onto a new higher value-added innovation trajectory (Tait 
et al., 2007). 
  Third key criticism against regulation is that it stagnate growth of the sector by creating rigid 
entry barriers. For example, the 1962 Act demanding proof of efficacy approval requirement has 
introduced high cost and long delays in pharmaceutical R&D process. As a result resources and 
capabilities required in taking a new product through the regulatory system ensure only MNC firms 
owners of those resources and capabilities to operate and dominate innovation cycle. Small 
companies totally rely on MNC firms to take their products through complete innovation cycle to 
markets or become acquisition targets, in both cases tailoring their innovation strategies to MNC firms. 
Tait et al., (2007) points out that regulation also determines overall company strategies, types of 
company that can succeed and the structure and dynamism of the sector as a whole and as a result 
overall structure of the pharmaceutical sector has remain unchanged for the last fifty years, despite 
numerous potentially path-breaking scientific discoveries. For example, Grabowski and Veron (1983) 
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argues that as a result Kefauver-Harris Amendment in 1962 the US FDA role has shifted from as 
essentially an evaluator of evidence and research findings at the end of R&D process to an active 
participant in the process itself. The 1962 amendment introduced proof of efficacy requirement for 
approval of new drugs and established regulatory controls over the clinical testing of new drug 
candidates. 
  This literature review suggests that a regulation can create artificial barriers in promoting 
disruptive innovations, affect evolution of sectors and reduce possibilities of the affordable healthcare 
and biotechnology products. Without disputing this observation this research aims to study what 
happens to growth and development of healthcare sectors in absence of any regulation. This review  
points out that regulation and innovation studies haven't paid enough attention to issue of absence of 
regulation and its impact on development of healthcare sectors. This research tries to fill that gap.   
 
     3. BACKGROUND: THE MEDICAL DEVICE SECTOR 
Medical devices sector includes a wide range of products such as medical gloves, bandages, 
syringes, condoms, contact lenses, disinfectants, X-ray equipment, surgical lasers, pacemakers, 
dialysis equipment, baby incubators and heart valves. The intended primary mode of action of a 
medical device on the human body, in contrast with that of medicinal products, is not metabolic, 
immunological or pharmacological. Medical device means any instrument, implant, machine, intended 
to be used, alone or in combination, for human beings for one or more specific purposes such as 
diagnosis, prevention, monitoring, treatment or alleviation of disease (Shah and Goyal, 2008). 
 In medical devices sector patents have much less importance in many segments of the device 
industry. Unlike pharmaceutical industry in the medical device industry, the basic principle can be 
patentable, but specific devices usually are not. Thus it is possible to design a medical device for a 
specific application in a number of different ways. The innovation often lies in the underlying principle 
being used in the particular application. For example, the concept of transducer was patentable, 
although specific implementations of the idea were simply design exercises and did not provide 
patentable material. In instrumentation products, patenting the design of the instrument itself is a futile 
exercise because it is not difficult to design another instrument in a different way that performs in 
exactly the same manner. In comparison to drugs, the device innovation process is characterised by a 
much higher degree of incremental change, which continues to occur throughout the various stages of 
pre-market testing. Surgical procedures that do not involve new products and new clinical practices 
tend to undergo a less formal evaluative process. They do not require pre-marketing regulatory 
approval, but in the case of major innovations payers tend to act as the gatekeepers requiring 
evidence prior to reimbursement and more generalized diffusion (Foote, 1991).   
 The global medical device market is currently valued at USD 210 billion in 2008 and has 
grown at a CAGR of 6% post 2000 (WHO, 2010).  The USA is largest consumer of medical devices 
and leads the world in the production of medical devices.  According to global statistics, 85% medical 
devices are manufactured in the USA, in Japan and in European Union countries while the same 
regions also account as major market for medical device. The USA has a medical device market 
valued at more than $100 billion in 2008, roughly 41% of the world’s total. It is followed by Japan 
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(10%), Germany (8%) and France (4%).  
 
TABLE 1 HIGHLIGHT OF MEDICAL DEVCIES FOR THE USA,EU AND JAPAN (Altenstetter, 2010, 
WHO, 2010) 
 
Medical devices USA EU Japan 
Production    
Global Share 51% 30% 10% 
Value (2005) $92.0 billion $38.0 billion $14.2 billion (2004) 
Consumption    
Global share 50% 30% 10% 
Value (2005) $90.2bn $38.1bn $19.0 (2004) 
 
Based on strong economic growth and large population China and India is increasingly emerging as 
an important medical device market. China’s overall market for medical devices is estimated to reach 
$5 billion in 2010 while Indian market is valued at $3billion. China and India are focusing on 
developing its medical device regulatory regimes and domestic market devices sector. The private 
healthcare sector in India is expanding significantly to meet the needs of India’s growing middle class, 
population of 300 million with disposable income and increasing medical expectations 
 
3.1 Status of medical device regulation 
The medical device industry (MDI) is a semi regulated sector globally and regulatory 
environments have significant implications for industry’s performance. Foote (1991) argues that public 
policies such as government regulation, product liability statutes, reimbursement rules, and 
government funding for basic research have had a significant impact on the production and diffusion of 
new medical devices. Medical devices around the world are classified based on their safety 
requirements and standards of quality to be set and several criteria are considered to evaluate the 
potential risk: degree of invasiveness, duration of contact, affected body system and local versus 
systemic effects. The regulation of medical devices is a vast and rapidly evolving field that is often 
complicated by legal technicalities. The early models for medical device regulation were based on 
drug regulation however due to inherent differences in drugs and devices uncritical application of drug 
model lead to serious difficulties. This led to evolution of a legally autonomous medical device 
regulatory framework. US took lead in development of medical device regulation in 1976 while 
European Union started framing their regulations in 1990.  
In the 1976 the US congress enacted the ‘medical device amendments’ which gave FDA authority to 
regulate medical devices. In 1990 US government pass the new law ‘The Safe Medical Devices Act’ 
that introduced pre-market notification as the primary safety and effectiveness in conjunction with a 
post-market strategy.   The post market regulation strategy included: mandatory reporting of adverse 
events or problems, device tracking systems, performance standards for class III devices and recall 
authority for FDA and imposition of civil penalties on manufacturer. In the US, the devices fall into 
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three categories – I, II or III, with class III devices with the highest risks and hence requiring the most 
stringent controls. In the US, medical devices can reach the market through two regulatory processes: 
the ‘pre-market approval’ (PMA) process or the ‘510(K)’ process. The most rigorous is the PMA 
process, which requires scientific evidence of safety and effectiveness for a device’s intended use 
obtained through ethically sound clinical trials. Class III devices, which support or sustain human life 
and include many novel cardiac devices, are subject to the PMA process. In contrast, a device that 
goes through the 510(K) process need only have evidence to demonstrate that it is substantially 
equivalent to, or at least as safe and effective as, another device that has already been cleared by the 
FDA (ie: the new or investigational device must be shown to be as safe and effective as a predicate 
device). The 510(K)’s route and evidentiary demands for ‘substantial equivalence’ makes it much 
quicker and cheaper for device makers than the PMA process, and the 510(K) process enables 
evolutionary changes to roll out more quickly, and it is such changes that are the hallmark of many 
device niches, including orthopaedic implants.  
In 1990 European Union issued directives under the ‘New Approach’ that harmonise different 
regulatory requirements for medical devices in different European countries and protect public health 
from unsafe medical devices. The ‘New Approach’ involved specifying only the general essential 
requirements those were general and mandatory. These essential requirements are divided into two 
types: General requirements applicable to all medical devices and the more specific requirements for 
‘design and construction’ that may or may not apply to a particular device. Medical devices that comply 
with New Approach directive carry the CE mark of conformity and can be marketed throughout the 
European Economic Area (EEA). In the EU, devices are categorised in a four-class scheme; I, IIa, IIb 
and III.  
Class I involves products such as hospital beds, wheelchairs, spectacles, gloves, Stethoscopes, etc.,  
Class II cover syringes for infusion pumps,  devices intended to channel blood, contact lenses, hearing 
aids etc., 
Class IIb includes hermodialysers, Urethral stents, insulin pens, prosthetic joint replacements, surgical 
lasers, blood bags, contact lens solutions, incubators etc., 
Class III devices cover absorbable sutures, cardiovascular & neurological catheters, heart valves, 
spinal stents, contraceptive devices, antibiotic bone cements, heparin-coated catheters etc. However 
these classes and devices are not rigidly categorised. For example in 2004 key products in the implant 
sector were reclassified from IIb to III, the highest risk category.  
Rather than a public authority, certification bodies implement and monitor compliance with New 
Approach directives, with varying involvement of a competent authority depending on the risk category 
of medical device. The conformity assessment procedures allow manufacturers to demonstrate 
devices satisfy essential requirements. Class I device manufacturer need to consider only one 
procedure while higher risk device developers can choose from one of the several conformity 
assessment procedures. These choices range from product testing to establishing a full quality 
assurance system that includes design control and risk analysis for Class III devices.  
In Japan, Ministry of Health, Labour and Welfare (MHLW) is a strong central ministry combining 
political authority and responsibility for the entire medical device regulatory framework, the national 
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health protection systems, public health as well as medical facilities. Medical device regulatory 
framework revised in 2005 combines both EU and FDA practices. Class I can be put on the market 
without any intermediary while Class II require a third party certification. Class III and Class IV devices 
need government approval which comes in two steps. The PMDA, a regulatory agency created in 
2004 reviews and recommends decision to the MHLW but has no authority to make final decisions. 
Altenstetter (2010) points out that unlike Europeans and Americans, the Japanese have not fully 
benefited or contributed to advances in the medical devices due to highly bureaucratic, lengthy and 
delayed approvals of new medical devices. It clearly suggests the key role of regulations in creating an 
environment that support innovative product development. 
 
3.2 The Indian medical device industry  
The medical technology market in India was estimated at US$2.75 billion in 2008 (NIPER, 2010). The 
Indian medical technology industry is highly competitive and fragmented, with domestic firms primarily 
manufacturing low technology products such as disposables/ medical supplies, and MNCs dominates 
high-end medical devices market. There are about 14000 medical devices marketed in India and more 
than 70% of devices are imported from advanced countries such as US, Japan, UK and Germany. 
MNCs from the USA are leading suppliers of devices with more than 28% products valued $400 mn 
coming to the India in 2008. There are almost 700 local manufacturers but most make low value 
products such as needles and catheters, leaving high-tech specialists devices such as transducer and 
heart-valve to MNCs such as St. Jude, GE, Siemens. Kamath (2010) explains the state of the Indian 
medical device industry that,   
 “The words India and medical technology are seldom used in the same sentence. An 
indigenous medical device industry has been virtually non-existent. Local players, with some 
exceptions, have struggled to shed the ‘low-tech, low quality’ tag. For instance doctors faulted local 
pacemakers for being too bulky and difficult to implant with leads (that connect the pacemaker to the 
heart muscle) fracturing easily”.  
Most MNCs are involved in distribution of medical technology products, though some of them 
have set up manufacturing operations in India. MNCs seeking to enter the industry typically form joint 
ventures with local manufacturers, establish subsidiaries or employ local agents to distribute their 
products. However, increasingly these companies are moving away from the practice of importing 
through local agents and setting up subsidiaries. According to Deloitte (2010) report key categories of 
items that are imported into India include imaging equipment, pacemakers, orthopaedic and prosthetic 
appliances, breathing and respiration apparatus, and dental equipment. 
This report further points out that even though India’s medical technology industry is primarily 
import dependent, at the same time, nearly 60% of what’s being manufactured is being exported. 
However, similar to domestic market Indian firms dominate low-tech equipment and the exports of high 
quality, high tech Indian products are negligible compared to other developing countries. Prof. 
Valiathan, the father of the Indian medical device industry explains: 
 “The Indian industry makes some low technology items which they are exporting. They don’t have any 
incentive to invest in hi-tech items” 
11 
 
(Telegraph, 2013) 
It is quite clear that similar to pharmaceutical and biotechnology products the medical device industry 
in India needs to create innovations appropriate to meet the healthcare needs of all income segments. 
In a resource constraint country such as India, domestic firms have to engineer devices that can be 
affordable, reliable, resilient, easy to distribute, and easy to use. Thus solutions have to be found by 
reducing costs, improving durability and focusing on serving basic healthcare needs. Prof. Valiathan 
highlights the social cost of import dependence: 
“Ten per cent of the imported items is accessed by only 10 per cent of our population. For the MNCs, it 
is a huge market, Rs 120 million. But we have a 1.2 billion population, if we want to give them access 
to such items, we need to develop them ourselves” 
(The Telegraph, 2013) 
 
This is where regulatory policies play a significant role due to their influence in facilitating or hindering 
development of appropriate medical devices. Despite this high percentage of imports and consumption 
till 2005 India did not at all regulate any of the medical devices (both local and foreign). In case of 
India absence of clear regulations, multiple levels of government authority involved in enforcing the 
guidelines, as well as inconsistent interpretation and application of the regulatory guidelines by 
customs officials at the ports, state drug controllers, and officials within CDSCO created a prolonged 
and cumbersome regulatory pathway, especially for new products (Deloitte, 2010).  In this context this 
research investigates key factors that hamper the development of inclusive innovations the Indian 
medical device industry.  
   
4. RESEARCH METHODOLOGY   
 This research explores the role of regulation and investigates its impact on the innovation and 
technological capability development in this important high-tech industry. Data collection involved 
conducting preliminary research to identify innovative Indian medical device firms and indigenously 
developed products. Following preliminary research, semi-structured interviews were conducted with 
key personnel from each company as well as key stakeholders associated with the industry. 
Participants were chosen from the medical, scientific, academic, policy, legislative and regulatory 
communities. Specifically interviews were conducted with a leading cardiac surgeon, a biomedical 
engineer, a local entrepreneur, a healthcare sector journalist, president of pharmaceutical industry 
association and a government official working with drug controller of India.  
Based on this preliminary data collection three companies; Shushrut-Adler, Medived, Sree 
Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST) were used as case studies. The 
firms were involved in developing products such as heart valves, orthopaedic implants, and blood 
bags.  
 
Table 2: Firms under study (company website, author communication with company, Deloitte, 2010)  
No 
 
Name of the firm 
 
Year of 
starting 
 
Medical 
device 
 
 
Impact 
12 
 
1 
 
Sree Chitra Tirunal 
Institute for Medical 
Sciences & 
Technology 
(SCTIMST) 
+ TTK Healthcare 
 
1974 
 
 
Heart Valve 
 
Cost is 50% less below the 
comparable heart valve 
produced by MNCs 
 
 
2 
 
Shushrut-Adler 
 
 
1973 
 
UMEX 
system 
 Absence of comparable 
products from MNCs in the 
Indian market 
 
3 
 
Medived 2007 Pacemaker Cost is Rs. 20,000 to 25,000 
below the comparable 
pacemakers produced by MNCs 
 
In each firm interviews were conducted with the Head of R&D and the CEO or Managing Director of 
the firm. Questions focused on the current status of the medical device industry, its regulatory 
framework and government initiatives to promote medical device research and manufacturing, and 
how it compares with India’s pharmaceutical/biotech industry. Open-ended questions and a relatively 
unstructured interview schedule were used to encourage participants to speak in their own words 
about their experiences, observations, opinions, and desires.  
 Data analysis was carried out using a theoretical framework based on innovation systems 
literature. Pattern matching technique was used for data analysis and data was categorised into 
following three themes;  
Theme 1 – Industrial Policy and government initiatives, Institutional support in form universities and 
research institutes public sector firms,  
Theme 2 - Entrepreneurship and role of Indian and MNC firms 
Theme 3 – Regulatory framework and its role.  
 
5.  Firms under study  
This section presents case studies of three firms and one innovation each of these firms developed. 
Sree Chitra Tirunal Institute is a research hospital but have an extended product development wing.  
 
5.1 Sree Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST) +TTK 
healthcare  
In 1973 Prof. Valiathan started Sree Chitra Institute with help of Royal Family of Travancore and in 
1976 initiated a project to develop indigenous heart valve in India. Most of the Indian hospitals import 
heart valves developed by MNC medical device companies such as Johnson & Johnson Services Inc. 
and Boston Scientific. In 1980 the institute was taken over by the central Indian government and 
Department of Science and Technology started providing funds for heart valve project. It was decided 
that the indigenous valve would be a mechanical device, not one that used human or animal tissue.  
However development of heart valve proved a very challenging process. The artificial valve must 
withstand the stress of opening and closing some 40 million times a year while the materials used for 
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the valve have to be compatible with blood and human tissues (Gopalraj, 2009). This project suffered 
a major setback when a model failed to work in sheep due to faulty material and the search for new 
material to replace it had to start anew. Finally, in December 1990, after clearance was obtained from 
the Institute’s ethics committee, the first Chitra valve was implanted in a patient. Prof. Valiathan 
explains the process: 
“Chitra Valve development happened in the late 70s. In a small institute in Trivandrum with limited 
resources, we could demonstrate that it could be done. By resources, I don’t mean just money but 
technology resources, like different types of materials, textiles, fine fabrication techniques; all these 
were available in India. Only thing is you had to shop around, and find them, integrate them and then 
only you could make a device. We showed that this was feasible.  
(The Telegraph, 2013) 
In late 1991, TTK Healthcare, one of the constituents of the TTK group, took the technology for the 
manufacture of the valve.  Raghu (2007) points out that the Chitra-TTK mechanical valves are sold at 
about a quarter cheaper than similar imported valves. But absence of specific regulation for the 
industry, and coverage under the Drugs and Cosmetics Act has created . Dr. Valiathan explains,  
“At the time, Sri Chitra was on the cusp of developing a range of local alternatives to imported devices, 
but we had no clue whose approval to take to launch product. Until there’s a law all decisions become 
ad-hock” (Kamath, 2007) 
 
 
5.2 Shushrut- Adler Surgicals  
The Shushrut Surgicals was established in 1973 by a first generation entrepreneur and started its 
operation by selling fracture management implants and instrumentations. In 1992 Shushrut embarked 
on development and manufacturing by setting of Adler Mediequip Pvt. Ltd. the eventual manufacturing 
company of the group.  The current managing director of the Shushrut-Adler Group, Ajay Pitre is a 
chairman of the medical device wing of the industry association body. He is also a member of the core 
committee advising the government on the formation and implementation of the Medical Devices 
Regulation standards in India. 
In post 1992 Shushrut developed collaboration with orthopaedic surgeons, academic institutes with in-
house engineering teams. One of these collaborations led to the creation of the first truly indigenous 
invention in the field of orthopaedics, the Universal Mini External Fixator system. Conceived by a 
group of eminent orthopaedic surgeons in Mumbai, led by Prof. B.B Joshi and Prof. Laud, the UMEX 
system enables clinical solutions in areas not addressed by products and devices from the Western 
world. UMEX enables effective treatment and rehabilitation in the case of extremity fractures (fractures 
in the hands and feet), crushing injuries of the extremities and paediatric deformities like club feet and 
club hand. The superior clinical outcomes possible with UMEX have led to adoption of the system by 
some prestigious centres in the U.K, Germany and U.S. However according managing director of the 
company lack of regulation in early years created hurdles in bringing innovative product to the market 
while in later years categorising devices under Drugs and Cosmetic Acts led increased cost of 
development by demanding inappropriate infrastructural changes.     
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5.3 MediVed 
Medived was started by local entrepreneur Dinesh Puri in 2007 with aim of developing medical 
devices appropriate and affordable for local populations. He explains the motivation: 
“I found that 90 % of the medical devices industry is controlled by the western world–US and Western 
Europe. It was even more interesting that 90 % of their revenues came from the western world. So I 
thought that how can you have people who live outside the western world consuming less than 10 % 
of these devices. In the case of pacemakers, the penetration level in the US is about a 1,000 per 
million population, and Western Europe has 1,300 per million. In India's case of it is just 15 per million. 
In China it is 50 per million. This was the motivation to get into the field of medical devices” 
(DARE, 2010) 
Realising the challenges in developing pacemaker from scratch Medived decided to go with 
collaboration route and brought in pacemaker technology from a South American company, CCC who 
had tried and tested technology and were supplying markets around the world for 35 years. After 
acquiring technology from CCC Medived embark on developing further innovations to reduce cost of 
production and refine technology to suit local needs without compromising quality. Similar to other 
medical devices pacemakers involves integration of multiple scientific disciplines and has to last for at 
least 10-15 years. Medived hired an engineer from Indian Satellite research organisation who used to 
make PCBs for satellites to work on engineering aspects of pacemaker manufacturing. In 2009 
Medived set up a vertically integrated manufacturing facility where everything associated with 
pacemakers would be manufactured. Dinesh Puri further explains the significance of indigenous 
pacemaker development for meeting healthcare needs of local population: 
“ In the US, these devices sell for $4,000-8,000. In India, we sell them between $1,000-2,000. It is a 
fact that many of these western companies also sell at lower prices than in the US. Our focus is to 
make the devices more relevant for our markets. In the US, everything is paid for by insurance. So 
people replace the devices every four to five years. In India, we are not used to that; we want the 
device to last for much longer time. In most emerging markets, 80percent of our healthcare is paid for 
by the patient. In our markets, we will have to find our own solutions” 
        (DARE, 2010) 
Similar to Sree Chitra institute’s heart valve Medived’s indigenously manufactured pacemaker faced 
obstacles in gaining market acceptance due to doctor’s doubts about quality of the indigenously 
developed medical devices. This issue certainly has direct links with absence of regulation to govern 
the Indian medical device industry as well as lack of trust in the Indian government’s regulatory set up.   
 
6 ANALYSIS AND DISCUSSION 
There are three key salient issues that describe the current status of the Indian medical device 
industry and they relate to flawed industrial policy, lack of entrepreneurship and government 
regulation. This paper focuses on the lack of regulation and its impact. Our analysis clearly show that 
lack of regulation had more serious impact on availability and access of appropriate medical devices to 
the poor population of India 
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6.1 Era of no regulation (1947-2005)  
In case of India till 2005 there was effectively no quality regulation for medical devices that 
were either imported or manufactured in the country. Dr Valiathan comments on neglect of the 
industry, 
 
“Devices suffered from neglect by the medical profession, technologists, industry and 
Government” 
 
Kamath (2007) suggests that in the early 1980s the government did realise the need for medical 
device regulation however problem was clear lack of understanding in how medical device works, its 
mechanism of action and criteria of performance measurement. Harper (2003) alleges that in some 
categories imports of used material was allowed into India and as a result low quality devices were 
used in the country. There was no regulatory control on how device actually works its technical 
specifications and performance. There was little information available on medical devices apart from 
that provided by companies for marketing purposes. All medical devices were sold in India without any 
monitoring by regulatory authority or reporting by hospitals. For instance, in case of Boston Scientific 
and Johnson and Johnson withdrawn of its stents worldwide in 2004, there was no independent 
information was available in India on how many of these devices may have been used or if any patient 
had reported any adverse event (Harper, 2003). 
 
6.1a Handicapped local manufacturers  
There are not set uniform standards for these products and as a result quality and 
performance are not tested. This lack of regulation created a significant hurdle for local manufacturer 
to develop products and enter the market domestic as well as international markets. These local 
manufacturers had no idea whose approval to take to launch product and all regulatory decisions were 
ad-hock. Local manufacturer struggled to sell their products in competitively in the market without 
proper authorisation and often fare poorly against MNC products which are approved by stringent 
western regulators and backed by huge amounts of clinical trials data.  Murthy (2004) points out that 
from 1994 till 2004 there were more than 11000 valve procedures were done per year in India, only 
1000 valves developed Sri Chitra Research Institute (a leading Indian research institute) were used 
even though it costs less than 50% of the average of all the imported valves. The Indian clinical 
community is averse to using devices of the Indian manufacture because of uncertain standards and 
lack of quality assurance. Thus absence of regulation and any direction from government severely 
handicapped local manufacturers in the market place.   
 
6.1b MNC’s Monopoly Rent  
MNC charged high prices with significant profit margins for their devices as the Indian clinical 
community is averse to using devices of the Indian manufacture because of uncertain standards and 
lack of quality assurance. MNC sold their products in the Indian market without really taking into 
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consideration of production cost as there were no local competitor to compete for low prices and no 
regulation to monitor their profit margins. There was no transparency in the production cost and selling 
prices varied widely in the market. Most of imported medical devices such as cancer diagnostic, 
medical imaging, ultrasonic scanning, plastic surgery equipment and polymerase chain reaction (PCR) 
technologies specifically at high-tech end were sold with high gross margins. Indian companies often 
fare poorly against premium global brands which are approved by stringent western regulators and 
backed by huge amounts of clinical trials data. Thus total lack of regulation created skewed market in 
favour of MNCs and as a result these companies could charge ‘monopoly rent’. A leading cardiac 
surgeon comments on domination of MNCs firm on the Indian medical device industry, 
 
 “We are compelled to import 90 per cent of high-end instruments, devices, etc for our 
hospitals at high cost and replace them every 3-5 years at still higher cost. This pushes up the 
cost of specialised care in cardiology, neurology, etc and makes them inaccessible to the 
majority of Indians. MNCs estimate their Indian market as 200 million who can pay --- they 
conveniently ignore the one billion who can't do it” 
 
This creates immense problem for securing access of these devices to much needed poor population 
of India as well as other developing countries. A leading bioengineer argues, 
 
“the lack of regulations, paucity of raw materials and unrestricted import of finished products 
all conspired to daunt an intending manufacture of biomedical devices” 
 
 
6.1c Mushrooming of counterfeit products  
  Without any regulation market was populated by spurious operators and counterfeit traders 
who used scrap material as raw material or import goods of uneven quality from Chinese 
manufacturers. Many small trading companies are mushrooming in the country which imports products 
from China, Korea and Taiwan at a very low rate, even lower than Indian firms’ production cost. A 
leading bioengineer involved in development of indigenous heart valve comments, 
  
“at the same time the market for the lower end disposables is vitiated by the unbridled manufacture of 
devices without any concern for GMP” 
 
The market is flooded with non-standard look-like counterfeit products, which are sold at very low 
prices. A CEO of orthopaedic implants company points out the impact of these spurious traders and 
counterfeit manufactures, 
 
“ I still lose more business to unregistered products than to MNCs”        
 
 Many of medical devices are implanted into the human body for critical care. Implanting a poor 
17 
 
quality or defective device can cost the life of the patient and therefore require minimum standards and 
some control on prices. This lack of monitoring in India could have serious consequences for poor 
patients’ healthcare as these people were recipients of cheap counterfeit and unsafe medical devices.  
In 2004 these consequences became apparent when state run JJ hospital in Mumbai used 
unapproved drug eluting stents on as many as 60 high risk cardiac patients. The stents were 
manufactured by Occam, a Netherlands-based company and marketed under the brand name Axxion. 
These stents were not approved for use even in Netherlands but they were marketed in unregulated 
Indian medical device market by the Mumbai-based trading company. Government shut down the 
importer and a local stent company as a result of this and both of them went to court showcasing 
absence of rules. As a result high court ordered government to set rules and standards for medical 
device industry.  
 
6.2 Era of wrong regulation (2005 – till now) 
  In 2005 taking cognisance of JJ Hospital case and court order the Indian government listed 10 
such medical devices under the Drugs and Cosmetics (D&C) Act, 1940. These products including 
cardiac stents, drug eluting stents, catheters, intra ocular lenses, IV cannulae, bone cements, heart 
valves, scalp vein sets, orthopaedic implants, and internal prosthetic replacements. These devices 
were mandated to get licenses for their manufacture, sale and distribution. These rules have been 
approved by the Ministry of Health and Family welfare and the guidelines issued came into force from 
March 1, 2006.  
  In India the major source of pharmaceutical regulations is the Drugs and Cosmetics Act 1940. 
This legislation applies to the whole of India and for all products whether indigenous or imported. The 
legislation is enforced by the office of the Drugs Controller General of India (DCGI). DCGI is 
authorised to handle product approval standards, permit clinical trials for introduction of new drugs, 
and regulate import license for new drugs. However there was serious problem with medical devices 
under Drugs and Cosmetics (D&C) Act. In Europe and US separate laws that govern medical devices 
and implants while pre-independence D&C Act is meant for drugs and cosmetic only. This was 
followed by a widespread debate on the legal status of medical devices. Several experts excluded 
medical devices from the drug list as the Drugs & Cosmetics Act does not cover medical devices. It 
was clearly evident that the regulatory framework and infrastructure designed to govern 
pharmaceutical and cosmetic products is totally inadequate for governing medical devices due to the 
nature of difference in products, their action in human body and packaging.  
By mid-2008, however, industry again began to experience inconsistent application of the current 
guidelines causing renewed confusion and delays. These problems were sourced in part to multiple 
levels of government authority involved in enforcing the guidelines, as well as inconsistent 
interpretation and application of the regulatory guidelines by customs officials at the ports, state drug 
controllers, and officials within CDSCO (Central Drugs Standard Control Organization). Some 
companies struggled to get licenses for products for more than 6-7 months even if they were in market 
for more than two decades and had received regulatory approval for their products from European 
regulators (Kamath, 2007). It was clearly evident that the regulatory framework and infrastructure 
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designed to govern pharmaceutical products is totally inadequate for governing medical devices due to 
the nature of difference in products, their action in human body and packaging. For example, concept 
sterility differs in pharmaceutical products and medical devices. A drug has to be manufacture in ‘clean 
room conditions’ requiring certain kind flooring, air-flow and energy requirement to minimize impurities. 
However in case of medical devices can be sterilised at the point of use and doesn’t require same 
production conditions such as pharmaceutical products. For instance orthopaedic surgeon orders 
different sizes of implants from the company and at the time of surgery sterilises only those which fits 
patients. A leading manufacturer of diagnostic devices explains the key issue, 
 
“This industry is considered to be a pharma segment but really does not belong there. The 
authorities themselves are not knowledgeable about diagnostics industry. A device cannot be 
regulated as a drug” 
 
By 2011 it became apparent that the D&C Act is not ideal for devices and rather than helping local 
authentic manufacturers, it endangers their survival. Globally, medical devices are regulated and the 
approvals acceptable in the world market are from the FDA in the US or the European CE certification. 
However, a similar regulatory body for Medical Devices is needed and not yet properly established in 
India. There is a clear lack of communication between various government departments, limited 
understanding of the issue on hand and severe infrastructural problems to implement any regulation. 
Dr. Valiathan points out difficulties in developing optimal regulation, 
 
“The Indian Medical Regulatory Authority (IMDRA) proposed by a Government Committee 
would have been optimal.  Thanks to turf war in the Government, it has been substituted by a 
Committee under the Drug Controller General of India.  It is too highly centralised and too 
bureaucratic to promote R&D and industrial activity in relation to medical devices and 
instrumentation.  Neither has become an Act yet” 
 
 The Indian government is still working toward establishing a medical regulatory regime but 
struggling to set up governance structure that can distinguish between medical devices and 
pharmaceuticals.  
 To conclude evidence presented here suggest that the Indian medical device was totally 
ungoverned from 1947 till 2005 and this was the period where local industry witnessed no growth, and 
domestic market was swamped by unaffordable devices by MNC and counterfeit products from 
spurious local traders. The authentic Indian device developers and manufacturers suffered the most 
as they struggle to again acceptability of their products due to lack of any regulation and regulating 
authority. MNCs enjoyed most benefit of the situation through monopoly rents severely restricting 
access of affordable healthcare to poor populations of India.   
 
7. CONCLUSIONS  
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This study focused on exploring linkage between regulation, inclusive innovation and sustainable 
development by focusing on the Indian medical device industry. The case studies presented in this 
research highlighted significant role of regulation in the development of appropriate inclusive 
innovations. It clearly indicates that in case of India an appropriate infrastructure do exists but clear 
absence of appropriate policies. This research highlighting role of regulatory policies in facilitating 
innovations reveals that without effective regulation, local authentic producers compete with 
counterfeit operators who use scrap metal as raw material, powerful MNCs and local traders who 
import goods of unproven quality. Local authentic producers have to compete on price with local 
counterfeit producers while fight with premium MNC brands in the high end of market. It is quite 
apparent that stringent regulations will control MNC as well as counterfeit producers and provide fair 
rules of game for local authentic producers. 
   Some of the developing countries such as Mexico, Brazil and others have set up regulatory 
framework based on US FDA and EU directives. These regulatory regimes contain common structural 
features that concerns with safety and effectiveness of the devices. Altenstetter (2010) while accepting 
convergence and internationalisation of medical device regulation argues that national states and 
national authorities have a significant role in devising regulatory framework that is suitable for local 
conditions. 
  However need is for ‘smart’ regulation than just framing some rules. It is also evident from 
Indian government’s attempt to regulate medical device market post 2005; rather than ensuring safe 
and effective products in fair market place, new act endanger inclusive innovations of local 
manufacturers and stifle supply of life saving devices. The Indian evidence suggests that, while 
regulation can create more equitable playing fields which can be vital for harnessing inclusive 
innovation, not just any regulation will do.   Thus it is quite evident that regulation is an important, 
indeed a vital component of innovation encouragement. The developing countries should create 
regulations that are focused on optimal safety, efficacy and quality parameters that match consumer 
expectations and are suitable to the local context.   
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